SCHEMBL613996

SCHEMBL613996

CNc1nc2cc(NS(=O)(=O)c3cccc(Cl)c3C)ccc2s1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 3/20 0.54
POLB P06746 1/20 0.54
LMNA P02545 4/20 0.49
ALDH1A1 P00352 4/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
THRB P10828 1/20 0.49
HPGD P15428 1/20 0.49
HSD11B1 P28845 3/20 0.49
HTT P42858 2/20 0.49
TP53 P04637 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
FSCN1 Q16658 1/20 0.47
ALOX15 P16050 1/20 0.46
MAPK1 P28482 1/20 0.46
HTR6 P50406 2/20 0.46
SLC40A1 Q9NP59 1/20 0.45
EDNRB P24530 1/20 0.45
EDNRA P25101 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL614858 0.91 LMNA (0.60) PKMLMNAALDH1A1MEN1KMT2A
SCHEMBL10089752 0.89 PKM (0.68) PKMPOLBLMNAALDH1A1MEN1
SCHEMBL614790 0.89 PKM (0.56) PKMPOLBLMNAALDH1A1MEN1
SCHEMBL615039 0.82 PKM (0.49) PKMPOLBLMNAALDH1A1MEN1
SCHEMBL617123 0.80 LMNA (0.62) PKMLMNAALDH1A1MEN1KMT2A
SCHEMBL617881 0.80 LMNA (0.62) PKMPOLBLMNAALDH1A1MEN1
SCHEMBL5338606 0.79 HSD11B1 (0.55) PKMLMNAALDH1A1MEN1KMT2A
SCHEMBL12909917 0.77 PKM (0.71) PKMPOLBLMNAALDH1A1MEN1
SCHEMBL5340610 0.77 HSD11B1 (0.50) LMNAALDH1A1MEN1KMT2ATHRB
SCHEMBL5343634 0.76 EDNRB (0.53) PKMPOLBLMNAALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120041207-A1 Compound STERIX LIMITED (GB) 2012-02-16 US disclosed
US-20120041207-A1 Compound STERIX LIMITED (GB) 2012-02-16 US disclosed
US-20110009448-A1 Compound STERIX LIMITED 2011-01-13 US disclosed
US-7786152-B2 Compound STERIX LIMITED (GB) 2010-08-31 US disclosed
US-7786152-B2 Compound STERIX LIMITED (GB) 2010-08-31 US disclosed
US-7786152-B2 Compound STERIX LIMITED (GB) 2010-08-31 US disclosed
US-20080114042-A1 Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer STERIX LIMITED (GB) 2008-05-15 US disclosed
US-20080114042-A1 Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer STERIX LIMITED (GB) 2008-05-15 US disclosed
US-20080114042-A1 Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer STERIX LIMITED (GB) 2008-05-15 US disclosed
US-7309715-B2 Compound STERIX LIMITED (GB) 2007-12-18 US disclosed
US-7309715-B2 Compound STERIX LIMITED (GB) 2007-12-18 US disclosed
US-7309715-B2 Compound STERIX LIMITED (GB) 2007-12-18 US disclosed
EP-1556040-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 Sterix Limited (GB) 2005-07-27 EP disclosed
US-20040143124-A1 Compound STERIX LIMITED (GB) 2004-07-22 US disclosed
WO-2004037251-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 STERIX LIMITED (GB) 2004-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114042-A1 Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer HSD11B1, HSD3B1, HSD11B2 PKM 2539/4885POLB 3518/4885LMNA 4577/4885
US-20110009448-A1 Compound NR4A1, GPR6, PRMT6 PKM 3481/4885POLB 4686/4885LMNA 3102/4885
US-20120041207-A1 Compound NR4A1, GPR6, PRMT6 PKM 3481/4885POLB 4686/4885LMNA 3102/4885
US-20040143124-A1 Compound NR4A1, CBR1, NR2C2 PKM 3558/4885POLB 4133/4885LMNA 2144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.